323 related articles for article (PubMed ID: 28692052)
1. Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer.
Ju HQ; Lu YX; Wu QN; Liu J; Zeng ZL; Mo HY; Chen Y; Tian T; Wang Y; Kang TB; Xie D; Zeng MS; Huang P; Xu RH
Oncogene; 2017 Nov; 36(45):6282-6292. PubMed ID: 28692052
[TBL] [Abstract][Full Text] [Related]
2. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
3. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
4. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
5. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
6. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
8. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
9. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
[TBL] [Abstract][Full Text] [Related]
10. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes.
Jain M; Brenner DA; Cui L; Lim CC; Wang B; Pimentel DR; Koh S; Sawyer DB; Leopold JA; Handy DE; Loscalzo J; Apstein CS; Liao R
Circ Res; 2003 Jul; 93(2):e9-16. PubMed ID: 12829617
[TBL] [Abstract][Full Text] [Related]
11. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
12. NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma.
Li Z; He Y; Li Y; Li J; Zhao H; Song G; Miyagishi M; Wu S; Kasim V
Oncogene; 2021 Dec; 40(50):6736-6747. PubMed ID: 34657129
[TBL] [Abstract][Full Text] [Related]
13. SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense.
Zhou L; Wang F; Sun R; Chen X; Zhang M; Xu Q; Wang Y; Wang S; Xiong Y; Guan KL; Yang P; Yu H; Ye D
EMBO Rep; 2016 Jun; 17(6):811-22. PubMed ID: 27113762
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
[TBL] [Abstract][Full Text] [Related]
15. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
18. Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro.
Chen X; Xu Z; Zhu Z; Chen A; Fu G; Wang Y; Pan H; Jin B
Int J Oncol; 2018 Oct; 53(4):1703-1712. PubMed ID: 30066842
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1.
Qin Y; Li L; Wang F; Zhou X; Liu Y; Yin Y; Qi X
Cell Physiol Biochem; 2018; 48(4):1628-1637. PubMed ID: 30071508
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
